Novartis' recent launch of Extavia in Europe may not significantly alter the multiple sclerosis landscape, but it points to the entrance of a formidable new player into the market. Extavia is ...

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease ...

EXTAVIA (interferon beta-1b) injection from Novartis The FDA has approved Extavia (interferon beta-1b injection, from Novartis) for the treatment of relapsing forms of multiple sclerosis (MS) to ...

Multiple sclerosis patients in England and Wales look set to have just one interferon therapy option after draft NICE guidance backed routine funding for Novartis’ Extavia and rejected other drugs.

Swiss drug giant Novartis received a boost this morning in the form of a US approval to market the multiple sclerosis therapy Extavia, its own branded version of Bayer’s interferon beta-1b drug ...

Novartis AG said Monday the U.S. Food and Drug Administration approved its drug Extavia, a form of interferon intended to treat multiple sclerosis. The FDA approved Extavia for relapsing-remitting ...

Sarah Carabott penned a humane story in today’s The Sunday Times of Malta (August 31, page 9) about the unnecessary tension and pain that sufferers from Multiple Sclerosis are having to go through as ...

Novartis has launched its multiple sclerosis drug Extavia in Europe, its branded version of Bayer's multiple sclerosis drug Betaseron. Novartis has launched its multiple sclerosis drug Extavia in ...

The Swiss drugmaker Novartis has been given the green light by the European Commission to sell Extavia, a multiple sclerosis drug. And although the firm has good reason to be happy, it shouldn’t be ...

EXTON, Pa., Jan. 11 BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December ...